Professor Simon G Best OBE FRSE

Professor Simon Best has over 25 years experience across the life science sector in pharmaceuticals, agbiotech, chemicals and industrial enzymes. Through this time, Simon has gained significant entrepreneurial and senior management experience of raising finance, deal formation and product commercialisation. He has founded two lifescience businesses; within Ardana one responsibility as CEO was taking the company public on the London Stock Exchange, and as Roslin Biomed's CEO he was responsible for the commercialisation of the technology that developed Dolly the Sheep, including the merger of the business into the US-listed biotech company Geron Corp. Earlier in his career, Simon was CEO and Managing Director of Zeneca Plant Science, where he managed the groups joint ventures and acquisition programmes. Simon is currently Entrepreneur-in-Residence and Partner at TVM Capital (Munich, Germany), Chairman of Advisory Board and non-exec Partner at PAR Equity (Edinburgh, UK), and Chairman at Edinburgh Technology Fund; and non-exec Director at Polytherics (London, UK), Targeted Growth (Seattle, USA), Ohmedics (Glasgow, UK) and Director International Potato Centre (Lima, Peru). He was formerly chairman of Neuro3D (Mulhouse, France) and ICRISAT (Hyderabad, India), and non-exec director of Avesthagen (Bangalore, India), and Direvo (Germany).

Chief Technical Officer & Founder of Aquapharm® Biodiscovery Ltd.

Dr Andrew Mearns Spragg FRSA

Dr Spragg gained a first class honours degree and PhD in marine microbiology from Heriot-Watt University and has grown the business from a university "Spin-Out" to a company of 20 FTEs. Since founding the business, Dr Spragg has successfully raised over £10M in equity and grant finance. Andrew developed the company whilst holding a Royal Society of Edinburgh Enterprise Fellowship in biotechnology; was awarded a John Logie Baird Award in Medical and Academic Science; and was also the recipient of the 2013 Gannochy Innovation Medal, and prize, from the Royal Society of Edinburgh for recognition of his achievements in biotechnology & innovation. In , Andrew's entrepreneurial achievements were further recognised when he won the Ernst & Young Entrepreneur of the year in Health Care (Scotland) prize.


Chief Scientific Officer

Dr Tim Morley

In his new role at Aquapharm, Dr Morley will be responsible for leading Aquapharm's in-house R&D programmes which address both pharmaceutical and non-pharma functional ingredient opportunities for the personal care and nutrition industries. Dr Morley has over 20 years experience in the pharmaceutical industry, which will prove invaluable as the company develops novel marine derived drug candidates. Dr Morley gained his PhD in Mechanistic Toxicology at Aberdeen University and holds an MSc in Biopharmacy, BSc in Pharmacology and BSc in Biochemistry.


Business Development Director

Mr Jon Williams

Mr Williams has built an enviable business development track record commercialising naturally derived products within a range of markets, including the pharmaceutical, food and personal care industries. Jon joined Aquapharm in from Summit plc where, as Managing Director of Summit (Wales), he established and led a new business unit focused on the exploitation of botanically derived bio-active ingredients. Prior to Summit plc, Jon successfully developed and led the European & Asian Business Development team at Avecia Biologics, a microbial-derived pharmaceutical business based in the UK. Jon holds a first class degree in Biological Sciences from Oxford University.